睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07654400,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;

    入选标准第 5 条

  3. Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

    入选标准第 9 条

    Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy;

    排除标准第 20 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    入选标准第 8 条

  5. Must have at least one measurable lesion as defined by RECIST v1.1;

    入选标准第 7 条

  6. Diagnosis of another malignancy within 5 years before the first dose;

    排除标准第 9 条

  7. Pregnant or breastfeeding women;

    排除标准第 24 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07654400,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent form and comply with the protocol requirements;
  2. No gender restriction;
  3. Age: ≥18 years;
  4. Expected survival time ≥3 months;
  5. Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;
  6. Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years, or fresh tissue samples;
  7. Must have at least one measurable lesion as defined by RECIST v1.1;
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  9. Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  10. No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;
  11. Organ function levels must meet the required criteria;
  12. Urine protein ≤1+ or ≤1000 mg/24h;
  13. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment. Serum pregnancy testing must rule out pregnancy, and the patient must not be breastfeeding. All enrolled trial participants (regardless of gender) should take adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. Use of chemotherapy, biological therapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose;
  2. Previous treatment with ADC drugs using topoisomerase I inhibitors as toxins;
  3. Small cell carcinoma with non-small cell carcinoma components indicated by pathology must be excluded;
  4. Use of immunomodulatory drugs within 2 weeks before the first dose of the study;
  5. Receiving long-term systemic corticosteroid therapy at a dose >10 mg/day of prednisone or equivalent before the first dose;
  6. History of severe cardiovascular or cerebrovascular diseases;
  7. Prolonged QTc interval, complete left bundle branch block, etc.;
  8. Active autoimmune diseases and inflammatory diseases;
  9. Diagnosis of another malignancy within 5 years before the first dose;
  10. Hypertension poorly controlled by two antihypertensive drugs;
  11. Patients with poorly controlled blood glucose;
  12. History of ILD/interstitial pneumonia treated with corticosteroids, etc.;
  13. Concomitant pulmonary diseases leading to clinically severe impairment of respiratory function;
  14. Presence of massive serous cavity effusion, or serous cavity effusion with symptoms, etc.;
  15. Imaging findings indicating that the tumor has invaded or encased major blood vessels in the chest, neck, pharynx, etc.;
  16. Any thrombotic event within 6 months before randomization;
  17. Patients with active central nervous system metastases;
  18. History of allergy to recombinant humanized antibodies or chimeric human-mouse antibodies, or allergy to any excipient components of the investigational drug, etc.;
  19. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation;
  20. Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy;
  21. Positive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  22. Active infections requiring systemic treatment, or occurrence of severe infection within 4 weeks before informed consent;
  23. Receipt of other unapproved clinical study drugs or treatments within 4 weeks before the first dose;
  24. Pregnant or breastfeeding women;
  25. History of severe neurological or psychiatric disorders;
  26. Presence of serious non-healing wounds, ulcers, or fractures within 4 weeks before signing informed consent;
  27. Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing informed consent;
  28. History of intestinal obstruction, inflammatory bowel disease, extensive bowel resection, or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea;
  29. Trial participants who plan to receive or have received live vaccines within 28 days before the first dose;
  30. Other conditions deemed by the investigator to be unsuitable for participation in this clinical trial.

引自 ClinicalTrials.gov, NCT07654400, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07654400,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07654400